Dow Jones
34.092,96 +6,92 (+0,02%) Nasdaq
11.816,32 +231,77 (+2,00%) Nikkei 225
27.402,05 +55,17 (+0,20%) EUR/USD
1,1010 +0,0016 (+0,14%) BTC-EUR
21.637,16 +513,91 (+2,43%) CMC Crypto 200
543,31 +300,63 (+123,88%)
Bristol-Myers Squibb Company (0R1F.L)
- GlobeNewswire
iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of
- GlobeNewswire
Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million
– $25 million equity investment from Bristol Myers Squibb at $18.25 per share – – Term loan facility from Hercules Capital provides up to $125 million – – Proceeds extend Kura’s cash runway into 2026, if term loan is fully drawn – SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced a $25 million equity investment from Brist
- GlobeNewswire
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
- Bristol Myers Squibb to receive access to Autolus’ RQR8 safety switch for use in cell therapy programs - - Autolus to receive an upfront payment, with potential for near term option exercise fees and development milestone payments plus royalties - LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into an agreement with Bristol M
